The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    comet II erbe
Previous Study | Return to List | Next Study

Endoscopic Gastric Mucosal Ablation as a Primary Obesity Therapy (COMET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05486338
Recruitment Status : Recruiting
First Posted : August 3, 2022
Last Update Posted : September 5, 2023
Sponsor:
Collaborator:
Erbe USA Incorporated
Information provided by (Responsible Party):
Erbe Elektromedizin GmbH

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

This study is intended to investigate safety and feasibility of a new weight loss technique called endoscopic Gastric Mucosal Ablation (GMA) that does not require surgery, but can be achieved using an endoscopic procedure.

Previous studies have suggested that weight loss after vertical sleeve gastrectomy (VSG) is partly due to the removal of normal stomach tissue suspected of having hormonal function. The study will investigate the minimally invasive treatment of obesity by means of argon plasma coagulation (APC) in combination with waterjet submucosal injection using HybridAPC.

As primary objective total body weight loss (TBWL) will be determined as body weight difference at the 6 months follow up (FU) visit after the last treatment session in comparison to the body weight prior to the initial treatment.

After signing the informed consent the doctor and research team will determine if the participant meets all requirements for this study. If a participant is confirmed to be a suitable candidate additional tests will be performed prior to the first application of GMA to assess the health status of the participant prior to treatment. During the screening and baseline visit the medical history and the medications of the participant will be reviewed.

After the treatments the participants will be followed for up to 12 months to assess the outcome of the GMA procedure.


Condition or disease Intervention/treatment Phase
Obesity Adiposity Device: Hybrid Argon Plasma Coagulation (HAPC) Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Endoscopic Gastric Mucosal Ablation (GMA) as a Primary Obesity Therapy Early Feasibility [COMET EF] - Step II
Estimated Study Start Date : September 2023
Estimated Primary Completion Date : August 2025
Estimated Study Completion Date : September 2025

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Gastric mucosal ablation
Participants receive submucosal injection followed by ablation of gastric mucosa using Hybrid Argon Plasma Coagulation (HAPC)
 Device: Hybrid Argon Plasma Coagulation (HAPC)
Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation to the gastric mucosa and preventing thermal damage to the muscle layer.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Total body weight loss [ Time Frame: 9 months ]
    Primary endpoint will be determined as the % of total body weight loss (TBWL). Total body weight loss (TBWL) will be determined as body weight difference at the final 6 months follow up (FU) visit after the last treatment visit in comparison to the body weight prior to the first treatment.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or females patients in the range of class I to class III obesity (BMI ≥ 30 to ≤ 40 with obesity-related comorbidity or BMI > 40 to BMI ≤ 45).
  2. Age 22 - 60 yrs.
  3. Treatment naïve for bariatric surgery or endoscopic bariatric therapy
  4. Agree to avoid any use of weight loss medications such as Meridia, Saxenda, Januvia, Xenical, Duromine or over the counter weight loss medications or supplements throughout the study.
  5. Women of childbearing potential (WOCBP) must agree to use acceptable contraception methods.
  6. Agree not to donate blood during their participation in the study.
  7. Able to comply with study requirements and understand and sign the Informed Consent Form.
  8. Stable weight defined as a fluctuation of less than 5% for at least 3 months prior to screening visit.
  9. History of failure to lose weight using conventional diet and lifestyle therapies.

Exclusion Criteria:

  1. Patients requiring exogenous insulin.
  2. HbA1c > 8.5 %
  3. Pregnant or breast-feeding or intending to get pregnant during the study.
  4. Unwilling or unable to complete the Visual Analogue Scale for pain assessment, patient questionnaires, or comply with study visits and other study procedures as required per protocol.
  5. History of diabetic ketoacidosis or hyperosmolar nonketotic coma.
  6. Probable insulin production failure, defined as fasting C-Peptide serum < 1 ng/mL (333 pmol/l).
  7. Previous use of any types of insulin for > 1 month (at any time, except for treatment of gestational diabetes).
  8. Change in diabetic treatment within the last three months.
  9. Use of glucose-lowering drugs for diabetes mellitus treatment with the exception of sulfonylurea (SU), biguanides and sodium dependent glucose co-transporter 2 (SGLT-2) inhibitors.
  10. Change of diabetes medication or doses 12 weeks prior to screening visit.
  11. Hypoglycemia unawareness or a history of severe hypoglycemia (more than 1 severe hypoglycemic event, as defined by need for third-party-assistance, in the last year).
  12. Known autoimmune disease, including but not limited to celiac disease, or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder.
  13. Previous upper GI surgery, or other endoscopic bariatric procedures or conditions, prior intra-gastric balloon or another gastric implant.
  14. History of diabetic gastroparesis.
  15. Known active hepatitis or active liver disease.
  16. Acute gastrointestinal illness in the previous 7 days.
  17. Known history irritable bowel syndrome, radiation enteritis or other inflammatory bowel disease, such as Crohn's disease.
  18. Known history of a structural or functional disorder of the esophagus that may impede passage of the device through the gastrointestinal tract or increase risk of esophageal damage during an endoscopic procedure, including Barrett's esophagus, esophagitis, dysphagia, achalasia, stricture/stenosis, esophageal varices, esophageal diverticula, esophageal perforation, or any other disorder of the esophagus.
  19. Known history of a structural or functional disorder of the esophagus, including any swallowing disorder, esophageal chest pain disorders, or drug refractory esophageal reflux symptoms.
  20. Known history of a structural or functional disorder of the stomach including gastroparesis, gastric ulcer, chronic gastritis, gastric varices, hiatal hernia (>3 cm), cancer or any other disorder of the stomach.
  21. Known history of chronic symptoms suggestive of a structural or functional disorder of the stomach, including any symptoms of chronic upper abdominal pain, chronic nausea, chronic vomiting, chronic dyspepsia or symptoms suggestive of gastroparesis, including post-prandial fullness or pain, post-prandial nausea or vomiting or early satiety.
  22. Currently have ongoing symptoms suggestive of intermittent small bowel obstruction, such as recurrent bouts of post-prandial abdominal pain, nausea or vomiting.
  23. Active H. pylori infection (Subjects with active H. pylori may continue with the screening process if they are treated with an appropriate antibiotic regimen, and eradication has been confirmed).
  24. History of coagulopathy, upper gastrointestinal bleeding conditions such as ulcers, gastric varices, strictures, congenital or acquired intestinal telangiectasia.
  25. Current use of anticoagulation therapy
  26. Obligate use of anti-inflammatory drugs that cannot be suspended for a minimum of 4 weeks post procedure
  27. Use of systemic glucocorticoids (excluding topical or ophthalmic application or inhaled forms) for more than 10 consecutive days within 90 days prior to the Screening Visit.
  28. Use of drugs known to affect GI motility (e.g. Metoclopramide).
  29. Receiving any weight loss medications such as Meridia, Xenical, Saxenda, Januvia, Duromine or over the counter weight loss medications at screening.
  30. Untreated/inadequately treated hypothyroidism, defined as an elevated Thyroid-Stimulating Hormone (TSH) level at Screening; if on thyroid hormone replacement therapy, must be on stable dose for at least 6 weeks prior to Screening.
  31. Persistent Anemia, defined as Hemoglobin <10 g/dL.
  32. Significant cardiovascular disease including known history of valvular disease, or myocardial infarction, heart failure, transient ischemic attack or stroke within the last 6 months.
  33. Known moderate or severe chronic kidney disease (CKD), with estimated glomerular filtration rate (eGFR) <45 ml/min/1.73m2 (estimated by MDRD).
  34. Known immunocompromised status, including but not limited to individuals who have undergone organ transplantation, chemotherapy or radiotherapy within the past 12 months, who have clinically-significant leukopenia, who are positive for the human immunodeficiency virus (HIV) or whose immune status makes the subject a poor candidate for clinical trial participation in the opinion of the Investigator.
  35. Active systemic infection.
  36. Known active malignancy within the last 5 years (with the exception of treated basal cell or treated squamous cell carcinoma).
  37. Subjects with an established diagnosis of Multiple Endocrine Neoplasia syndrome type 1.
  38. Not a candidate for surgery or general anesthesia.
  39. Active illicit substance abuse or alcoholism.
  40. Current smoker or smoking history in the last six months.
  41. Participating in another ongoing clinical trial of an investigational drug or device.
  42. Any other mental or physical condition which, in the opinion of the investigator, makes the subject a poor candidate for clinical trial participation.
  43. Other medical condition that does not allow for endoscopic procedure.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05486338


Contacts
Layout table for location contacts
Contact: Jan Miller, RN, CCRA 800-778-3723 ext 344 jan.miller@erbe-usa.com
Contact: Hartmut Hahn, Dr.rer.nat. +497071755225 hartmut.hahn@erbe-med.com

Locations
Layout table for location information
United States, Florida
Mayo Clinic Recruiting
Jacksonville, Florida, United States, 32224
Contact: Dilhana Badurdeen, MBBS         
United States, North Carolina
True You Weight Loss Recruiting
Cary, North Carolina, United States, 27513
Contact: Christopher McGowan, MD         
Sponsors and Collaborators
Erbe Elektromedizin GmbH
Erbe USA Incorporated
Investigators
Layout table for investigator information
Principal Investigator: Dilhana Badurdeen, MBBS Mayo Clinic, Jacksonville, Florida
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: Erbe Elektromedizin GmbH
ClinicalTrials.gov Identifier: NCT05486338    
Other Study ID Numbers: GMA_2022_01
First Posted: August 3, 2022    Key Record Dates
Last Update Posted: September 5, 2023
Last Verified: September 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Erbe Elektromedizin GmbH:
Hybrid Argon Plasma Coagulation
Endoscopic bariatric therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Obesity
Overweight
Overnutrition
Nutrition Disorders
Body Weight